Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer
2019 · British Journal of Cancer · 94 citations
https://doi.org/10.1038/s41416-019-0531-5
M
Marion Jacquin
Inserm(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
39
Papers
665
Citations
13
h-index
14
i10-index
Marion Jacquin is an academic researcher from Inserm. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & Cancer Research and Treatments. The author has an h-index of 13, co-authored 34 publications.
Papers by this author
worksEvaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)
2023 · BMC Cancer · 21 citations
https://doi.org/10.1186/s12885-023-11065-0
UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity
2025 · Cell Reports Medicine · 0 citations
https://doi.org/10.1016/j.xcrm.2025.102196
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat